Increased levels of immune inhibitory CD34+ progenitor cells in the peripheral blood of patients with node positive head and neck squamous cell carcinomas and the ability of these CD34+ cells to differentiate into immune stimulatory dendritic cells

Otolaryngology - Head and Neck Surgery

Volumn 125, Issue 3, 2001, Pages 205-212

  Lathers, Deanne M R ^a,b   Achille, Nicholas ^b   Kolesiak, Kristin ^b   Hulett, Kevin ^b   Sparano, Anthony ^c   Petruzzelli, Guy J ^b   Young, M Rita I ^a,b  

^a HINES VA HOSPITAL   (United States)

^b Department of Pathology ^*  (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANTIGEN PRESENTATION; ARTICLE; BLOOD; CELL DIFFERENTIATION; DENDRITIC CELL; HEAD AND NECK TUMOR; HUMAN; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SECRETION; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TUMOR RECURRENCE;

ANTIGEN PRESENTATION; ANTIGENS, CD34; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEAD AND NECK NEOPLASMS; HUMANS; INTERFERON TYPE II; NEOPLASM RECURRENCE, LOCAL; T-LYMPHOCYTES;

EID: 0035464233     PISSN: 01945998     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhn.2001.117871     Document Type: Article

References (16)

1. Heimdal JH, Aarstad HJ, Klementsen B, et al. Peripheral blood mononuclear cell (PBMC) responsiveness in patients with head and neck cancer in relation to tumour stage and prognosis. Acta Otolaryngol 1999;119:281-4.
2. Barrera JL, Verastegui E, Meneses A, et al. Combination immunotherapy of squamous cell carcinoma of the head and neck; a phase 2 trial. Arch Otolaryngol Head Neck Surg 2000;126:345-51.
3. Hadden JW, Endicott J, Baekey P, et al. Interleukins and contrasuppression induce immune regression of head and neck cancer. Arch Otolaryngol Head Neck Surg 1994;120:395-403.
4. + cells in cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 1995;1:95-103.
5. + immune suppressive cells in the peripheral blood of patients with head and neck cancer. Ann Otol Rhinol Laryngol 2000;109:749-54.
6. Young MRI, Wright MA, Lozano Y, et al. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer 1996; 67:333-8.
7. + hermatopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor α: II. Functional analysis. Blood 1997;90:1458-70.
8. Grabbe S, Kampgen E, Schuler G. Dendritic cells: multi-lineal and multi-functional. Immunol Today 2000;21:431-3.
9. + melanoma patients by mature monocyte-derived dendritic cells. J Immunol 2000;165: 3492-6.
10. Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000;6:2175-82.
11. + cells from the peripheral blood of head and neck cancer patients. J Leuko Biol 1999; 65:623-8.
12. + cells. Int J Cancer 1997;73:663-9.
13. Young MRI, Wright MA, Matthews JP, et al. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-β and nitric oxide. J Immunol 1996;156:1916-22.
14. + T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 1999;162:5728-37.
15. Steube KG, Meyer C, Drexler HG. Secretion of functional hematopoietic growth factors by human carcinoma cell lines. Int J Cancer 1998;78:120-4.
16. Burke F, Relf M, Negus R, et al. A cytokine profile of normal and malignant ovary. Cytokine 1996;8:578-85.